| Identification | Back Directory | [Name]
DWK-1339 | [CAS]
1018946-38-7 | [Synonyms]
DWK-1339
SNU-0039
DWK-1339;DWK 1339;DWK1339
2-(3,4-DiMethoxy-phenyl)-5-(3-Methoxy-propyl)-benzofuran
Benzofuran, 2-(3,4-diMethoxyphenyl)-5-(3-Methoxypropyl)-
2-(3,4-dimethoxyphenyl)-5-(3-methoxypropyl)-1-benzofuran | [Molecular Formula]
C20H22O4 | [MDL Number]
MFCD22665705 | [MOL File]
1018946-38-7.mol | [Molecular Weight]
326.39 |
| Chemical Properties | Back Directory | [storage temp. ]
Store at -20°C | [solubility ]
DMF: 30mg/mL; DMSO: 30mg/mL; Ethanol: 2mg/mL | [form ]
A crystalline solid | [color ]
White to off-white |
| Hazard Information | Back Directory | [Description]
DWK-1339 is an inhibitor of amyloid-β (Aβ) aggregation. It inhibits aggregation of monomeric Aβ (1-42) (Aβ42) and induces disaggregation of Aβ42 fibrils in vitro when used at concentrations ranging from 3.1 to 50 μM. DWK-1339 (10 μM) reduces Aβ42-induced toxicity in HT-22 cells. In vivo, DWK-1339 (10 mg/kg) increases step-through latency in a passive avoidance test and increases spontaneous alteration in the Y-maze compared with vehicle control mice in a mouse model of Aβ42-induced acute Alzheimer''s disease. It also decreases brain levels of Aβ42 and increases spontaneous alteration in the Y-maze in the APP/PS1 transgenic mouse model of Alzheimer''s disease. | [Uses]
DWK-1339, is an orally active and blood-brain-barrier-permeable Aβ-aggregation inhibitor, used in the research of Alzheimer''s disease. | [in vivo]
MDR-1339 (0.1-10 mg/kg, p.o.) dose-dependently restores the passive avoidance responses in mice models of Alzheimer's disease (AD), with an ED50 of 0.19 mg/kg. MDR-1339 (30 and 100 mg/kg, p.o. daily for 8 weeks) significantly improves spontaneous alternation, and reduces the Aβ1-40 and Aβ1-42 levels in APP/PS1 mice[1]. | [storage]
Store at -20°C |
|
| Company Name: |
Twochem Co.Ltd.
|
| Tel: |
021-58111628 15800915896 |
| Website: |
cn.twochem.com |
|